Instem plc
("Instem" or the "Company")
Result of AGM
Instem (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, announces that at its Annual General Meeting held today, all resolutions were duly passed. The results of the proxy voting position received in advance of the meeting are reported below:
| No. | Resolution | For | % For | Against | % Against | Withheld |
| 01 | Accounts and Reports | 13,886,707 | 89.98% | 1,545,989 | 10.02% | 2,094,614 |
| 02 | Re-elect R A Bandali | 17,527,120 | 100.00% | 190 | 0.00% | 0 |
| 03 | Re-elect D M Sherwin | 13,727,503 | 88.95% | 1,705,343 | 11.05% | 2,094,464 |
| 04 | Re-elect M F McGoun | 13,566,252 | 87.91% | 1,866,594 | 12.09% | 2,094,464 |
| 05 | Re-appoint Auditors | 17,527,120 | 100.00% | 190 | 0.00% | 0 |
| 06 | Auditors Remuneration | 17,527,310 | 100.00% | 0 | 0.00% | 0 |
| 07 | Allot Shares | 16,989,283 | 96.93% | 538,027 | 3.07% | 0 |
| 08 | Allot Equity Securities | 16,989,283 | 96.93% | 538,027 | 3.07% | 0 |
| 09 | Make Market Purchases | 17,527,310 | 100.00% | 0 | 0.00% | 0 |
Notes:
· The full text of each of the resolutions is contained in the Notice of Annual General Meeting dated 16 May 2022, which is available on the Company's website at https://www.instem.com.
· Proxy appointments which gave discretion to the Chairman of the AGM have been included in the "For" total for the appropriate resolution.
· A "Withheld" vote is not a vote in law and is not counted in the calculation of the proportion of the votes cast "For" or "Against" a resolution.
· The issued share capital of the Company as at 09 June 2022 was 22,676,808 ordinary shares of 10p each. No shares are held in treasury.
For further information, please contact:
| Instem plc | Via Walbrook |
| Phil Reason, CEO | |
| Nigel Goldsmith, CFO | |
| | |
| Singer Capital Markets (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Peter Steel | |
| | |
| Stifel Nicolaus Europe Limited (Joint Broker) | +44 (0) 20 7710 7600 |
| Ben Maddison |
|
| Alex Price |
|
|
|
|
| Walbrook Financial PR | +44 (0) 20 7933 8780 |
| Tom Cooper | instem@walbrookpr.com |
| Nick Rome | |
| | |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
